Good news, bad news for Mannkind's inhaled insulin system
Tuesday, September 16, 2008 - 13:42
in Health & Medicine
Company releases test results showing that its Technosphere insulin delivery system is as effective for diabetics as injections. But investors are still wary about safety, and Mannkind's stock slumps. Even after biotechnology company MannKind Corp. released new data on its experimental insulin inhaler today, the Valencia-based company has been unable to assuage the safety concerns that decimated its stock in April.
Read the whole article on LA Times - Health
More from LA Times - Health
Related
- Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?Wed, 23 Sep 2009, 12:30:21 EDT
- Protein critical for insulin secretion may be contributor to diabetesMon, 26 Oct 2009, 15:09:46 EDT
- Impact of insulin pump under studyTue, 4 Nov 2008, 16:57:28 EST
- Novel mechanisms controlling insulin release and fat deposition discoveredTue, 13 May 2008, 10:28:37 EDT
- Systems properties of insulin signaling revealedFri, 20 Jun 2008, 0:42:43 EDT